Results from a phase 1 first-in-human study evaluating NGM621, an anti-complement C3 antibody, in geographic atrophy secondary to age-related macular degeneration showed the therapy was safe and well tolerated.
“NGM621 was well tolerated up to 15 mg dosed twice in this phase 1 study with no safety signals, supporting the continued clinical development of NGM621,” Charles C. Wykoff, MD, PhD, said at the virtual Angiogenesis, Exudation, and Degeneration meeting.
The novel monoclonal antibody potently inhibits C3 and prevents downstream activation of the complement cascade. The primary
Uncategorized